Table 2. Geometric mean concentrations/titers for routine vaccine components (95% CI).
| Antigen (cut-off) |
Study groups | Ratio of GMTs 4CMenB+Para to 4CMenB (95% CI) | |||
|---|---|---|---|---|---|
| Timing | 4CMenB | 4CMenB + Para | Men C | ||
|
Diphtheria (ELISA IU/mL) |
Post-3rd dose |
1.93 (1.78–2.1) n = 140 |
1.84 (1.7–2.0) n = 135 |
2.43 (2.24–2.64) n = 132 |
0.95 (0.85–1.07) |
| Pre-booster |
0.38 (0.34–0.43) n = 119 |
0.37 (0.33–0.42) n = 115 |
0.46 (0.33–0.42) n = 131 |
0.97 (0.82–1.16) | |
| Post-booster |
4.48 (3.96–5.07) n = 118 |
4.31 (3.81–4.87) n = 120 |
5.23 (4.6–5.95) n = 119 |
0.96 (0.81–1.14) | |
|
Tetanus (ELISA IU/mL) |
Post-3rd dose |
1.83 (1.62–2.06) n = 140 |
1.58 (1.39–1.78) n = 135 |
2.0 (1.77–2.25) n = 132 |
0.86 (0.73–1.02) |
| Pre-booster |
0.39 (0.33–0.45) n = 119 |
0.35 (0.3–0.41) n = 115 |
0.41 (0.36–0.48) n = 131 |
0.91 (0.73–1.14) | |
| Post-booster |
4.31 (3.73–4.98) n = 118 |
3.76 (3.26–4.34) n = 120 |
4.8 (4.18–5.25) n = 119 |
0.87 (0.71–1.07) | |
|
PRP (µg/mL) |
Post-3rd dose |
1.6 (1.34–1.92) n = 140 |
1.55 (1.29–1.86) n = 135 |
1.72 (1.43–2.06) n = 132 |
0.96 (0.75–1.24) |
| Pre-booster |
0.81 (0.7–0.94) n = 119 |
0.76 (0.65–0.89) n = 115 |
0.76 (0.67–0.86) n = 131 |
0.94 (0.76–1.16) | |
| Post-booster |
11 (8.68–13) n = 118 |
9.8 (7.97–12) n = 120 |
14 (11–16) n = 119 |
0.92 (0.68–1.23) | |
|
Anti-HBs (mIU/mL) |
Post-3rd dose |
290 (211–398) n = 65 |
332 (243–455) n = 66 |
268 (192–375) n = 60 |
1.15 (0.73–1.79) |
| Pre-booster |
60 (46–78) n = 102 |
79 (60–102) n = 101 |
92 (67–126) n = 107 |
1.31 (0.9–1.9) | |
| Post-booster |
2492 (1875–3312) n = 98 |
2408 (1804–3214) n = 95 |
3408 (94–100) n = 94 |
0.97 (0.64–1.45) | |
|
Poliovirus 1/Dilution Post-3rd dose |
Poliovirus 1 |
120 (96–150) n = 123 |
98 (79–123) n = 120 |
127 (101–159) n = 119 |
0.82 (0.6–1.12) |
| Poliovirus 2 |
92 (72–118) n = 123 |
75 (58–97) n = 120 |
114 (90–144) n = 117 |
0.82 (0.57–1.16) | |
| Poliovirus 3 |
320 (263–391) n = 123 |
279 (228–341) n = 120 |
398 (322–492) n = 117 |
0.87 (0.66–1.15) | |